Showing 2642 results
- Featured News /
Latest oncology resources and news surrounding Novartis data featured at American Society of Clinical Oncology (ASCO)
- Media Release /Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap…
- Featured News /
As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.
- Statement /
Novartis condemns the war in Ukraine and has been providing humanitarian support, financial donations as well as considerable volumes of medicines to those people impacted by the war.
- Featured News /
Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.
- Media Release /Six African nations will join a partnership pioneered in Ghana using technology to track and better tackle sickle cell disease (SCD) Includes expanded rollout of an app to track babies diagnosed…
- Media Release /Kisqali is the only CDK4/6 inhibitor with consistent overall survival (OS) benefit seen across all three Phase III trials, with the longest median OS benefit ever reported for HR+/HER2- mBC1-10 OS…
- Media Release /Biomarker analysis from Phase III SOLAR-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1 mutations and genes implicated in CDK4/6i resistance1 Piqray plus…
- Media Release /Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in…
- Featured News /
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
Pagination
- ‹ Previous page
- 1
- …
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- …
- 265
- › Next page